Identification and development of effective anti-cancer drugs using PNC as a phenotypic marker for metastatic potential of cancer cells� Methods: To identify compounds selectively targeting the metastatic state, we used the perinuclear compartment (PNC), a complex nuclear structure associated with metastatic behaviors of cancer cells, as a phenotypic marker for a high-content screen of over 140,000 structurally diverse compounds� Extensive medicinal chemical optimization of a screening hit yielded metarrestin, which has been evaluated for in vitro and in vivo effi-cacy against xenograft tumor growth and metastasis from three type's human cancers in animal models� Biochemical and cellular characterizations have identified some of the modes of action for metarrestin� Results: Metarrestin disassembles PNCs in multiple cancer cell lines, inhibits invasion in vitro, blocks metastatic development in three mouse models of human cancer, and extends survival of mice in a metastatic pancreatic cancer xenograft model even when macrometastasis have developed� Metarrestin induces little toxicity or discernable adverse effects in animals when treated daily up to 4 months� Metarrestin selectively disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription in cancer cells, at least in part by interacting with the translation elongation factor eEF1A2� Thus, metarrestin represents a potential therapeutic approach for the treatment of metastatic cancer� Conclusion: PNC and nucleoli may play roles in metastatic cancer development�
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